Anti-TIM-3 Monoclonal Antibody TQB2618 clinical trials
How each study uses Anti-TIM-3 Monoclonal Antibody TQB2618 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-TIM-3 Monoclonal Antibody TQB2618 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB2618 injection
- 5
Studies by the year they started
10 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Penpulimab (4) · Catequentinib hydrochloride (1) · Anlotinib (1) · Paclitaxel (1) · Cisplatin (1) · Toripalimab (1) · Benmelstobart (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Anti-TIM-3 Monoclonal Antibody TQB2618 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06010901Written as TQB2618 injectionHow we know
- A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05783921Written as TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or CarboplatinHow we know
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05563480Written as TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride InjectionHow we know
- A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05975645Written as TQB2618 injectionHow we know
- Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05834543Written as TQB2618 injection, Penpulimab injection, Paclitaxel, CisplatinHow we know
- Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced MelanomaStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05451407Written as TQB2618 injectionHow we know
- To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory LymphomaStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05400876Written as TQB2618 injectionHow we know
- Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid TumorsStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05645315Written as TQB2618 injection and TQB2450 injectionHow we know
- Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05426798Written as TQB2618 injection azacitidine, AZA decitabine, DACHow we know
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid TumorsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04623892Written as TQB2618 injectionHow we know